When should patients with ANCA-associated vasculitis be switched from induction to maintenance therapy?

Nature Clinical Practice Nephrology

Volumn 3, Issue 5, 2007, Pages 236-237

  Flossmann, Oliver ^a   De Groot, Kirsten ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b Klinikum Offenbach GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MAINTENANCE THERAPY; PRIORITY JOURNAL; RELIABILITY; REMISSION; SHORT SURVEY; TREATMENT DURATION; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AZATHIOPRINE; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; REMISSION INDUCTION; VASCULITIS;

EID: 34247584505     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0468     Document Type: Short Survey

References (11)

1. Westman KW et al. (1998) Relapse rate, renal survival and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 9: 842-852
2. Reinhold-Keller E et al. (2000) An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43: 1021-1032
3. Hoffman GS et al. (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116: 488-498
4. Jayne DR and Rasmussen N (1997) Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 72: 737-747
5. Jayne D et al. (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 36-44
6. de Groot K et al. (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 2461-2469
7. de Groot K and Jayne D (2005) What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. Clin Nephrol 64: 480-484
8. Hellmich B et al. (2006) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on ANCA-associated vasculitis. Ann Rheum Dis [doi: 10.1136/ard.2006.062711]
9. Reinhold-Keller E et al. (2002) High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 47: 326-332
10. Hogan SL et al. (2005) Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143: 621-631
11. Smith KG et al. (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54: 2970-2982